Source / episode info
- **Episode:**346
- **Title:**Divine Intervention Episode 346 – Cardiovascular Pharmacology for The USMLE Step 2CK/3 Exams Part 1 (+ 11/1-5 Step 2CK/3 Course Reminder)
- **Published:**2021-10-18
- Source:Episode page
One-liner
This episode provides a comprehensive review of advanced cardiovascular pharmacology, focusing on antiarrhythmic agents (Procainamide, Amiodarone), the differential use and side effects of Calcium Channel Blockers (CCBs) in hypertension, angina, and obstetrics, and critical drug associations like Nimodipine for vasospasm.
High-yield summary
- WPW Syndrome: The acute treatment of WPW syndrome is Procainamide, a Class 1A antiarrhythmic; AV nodal blockers (Verapamil/Diltiazem) are contraindicated due to risk of rapid conduction down the accessory pathway.
- Stable VT Management: For hemodynamically stable ventricular tachycardia (VT), Amiodarone is the drug of choice for initial management, while unstable VT requires immediate synchronized cardioversion.
- CCB Side Effects & Treatment: Dihydropyridine CCBs cause peripheral edema due to arteriolar dilation -> increased capillary hydrostatic pressure; this side effect can be mitigated by administering ACE inhibitors, which dilate postcapillary venules.
- SAH Vasospasm: Following a subarachnoid hemorrhage (SAH), the prevention of cerebral vasospasm is achieved with Nimodipine (a CCB).
- CCB Classification & Use: Dihydropyridine CCBs are primarily vascular dilators and cause reflex tachycardia; non-dihydropyridine CCBs (Verapamil, Diltiazem) are more cardio-selective but carry risks like hyperprolactinemia.
- Tocolytics: The choice of tocolytic depends on gestational age: Endomethacin is first-line 30 weeks; Nifeprone is first-line > 30 weeks.
Learning objectives
- Differentiate the appropriate antiarrhythmic agent for acute WPW syndrome versus chronic management.
- Analyze the clinical utility and side effects of dihydropyridine vs non-dihydropyridine calcium channel blockers in various cardiovascular settings (hypertension, angina).
- Identify the specific tocolytic agents based on gestational age criteria (\le 30 weeks vs > 30 weeks).
- Recognize the pharmacological basis for Nimodipine's use in preventing vasospasm post-SAH.
- Correlate drug side effects (e.g., Amiodarone, Verapamil) with specific endocrine or organ system toxicities.